Market news

In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.

Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.

The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.

REGENXBIO Inc. (NASDAQ:RGNX) shares tumbled 35% after the U.

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

Aug 24 () - Regenxbio said on Monday the U. Food ‌and Drug Administration has ‌placed its experimental gene therapy for ​Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.

Regenxbio (RGNX) does not plan to resubmit the biologics license application for its investigational

Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.

Regenxbio's (RGNX) Duchenne muscular dystrophy gene therapy appears approvable, with efficacy compar

REGENXBIO (RGNX) has an average rating of overweight and mean price target of $26.25, according to a

REGENXBIO (RGNX) has an average rating of overweight and mean price target of $26.25, according to a

Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights.

Tipranks Press Release.

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD using subretinal delivery and diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the American Society of Retina Specialists (ASRS) 44th Annual Meeting in Montreal, Canada.